Regulatory T cells as therapeutic target in Hodgkin's lymphoma

Bibliography

• Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117(5):1167-74
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81
   PubMed Web of Science ®Google Scholar
• Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor ζ chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53(23):5613-6
   PubMed Web of Science ®Google Scholar
• Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999;96(5):2233-8
   PubMed Web of Science ®Google Scholar
• Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64
   PubMed Web of Science ®Google Scholar
• Coulie PG, Karanikas V, Lurquin C, et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002;188:33-42
   PubMed Web of Science ®Google Scholar
• Herin M, Lemoine C, Weynants P, et al. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 1987;39(3):390-6
   Google Scholar
• June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117(5):1204-12
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Simoes B, Schmid C. Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Curr Opin Oncol 2004;16(2):167-73
   Google Scholar
• Gabrilovich DI, Nadaf S, Corak J, et al. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170(1):111-9
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170(1):101-10
   PubMed Web of Science ®Google Scholar
• Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7(12):1339-46
   PubMed Web of Science ®Google Scholar
• Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007;19(2):217-23
   PubMed Web of Science ®Google Scholar
• Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103(5):1755-62
   PubMed Web of Science ®Google Scholar
• Ekstrand BC, Horning SJ. Hodgkin's disease. Blood Rev 2002;16(2):111-7
   Google Scholar
• Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84(5):1361-92
   PubMed Web of Science ®Google Scholar
• Kuppers R, Yahalom J, Josting A. Advances in biology, diagnostics, and treatment of Hodgkin's disease. Biol Blood Marrow Transplant 2006;12(1 Suppl 1):66-76
   PubMed Web of Science ®Google Scholar
• Kuppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res 2002;84:277-312
   PubMed Web of Science ®Google Scholar
• Bechtel D, Kurth J, Unkel C, et al. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 2005;106(13):4345-50
   PubMed Web of Science ®Google Scholar
• Kulwichit W, Edwards RH, Davenport EM, et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95(20):11963-8
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Sherritt M, Thomson S, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003;101(8):3150-6
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007;110(7):2620-30
   PubMed Web of Science ®Google Scholar
• Franzke A, Koenecke C, Geffers R, et al. Classical Hodgkin's lymphoma: molecular evidence for specific alterations in circulating T lymphocytes. Tumour Biol 2006;27(6):329-33
   PubMed Web of Science ®Google Scholar
• Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21(19):3601-8
   PubMed Web of Science ®Google Scholar
• Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998;16(3):830-43
   PubMed Web of Science ®Google Scholar
• Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996;14(5):1421-30
   PubMed Web of Science ®Google Scholar
• Longo DL, Duffey PL, Hubbard SM, et al. Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast. J Clin Oncol 1992;10(8):1367-9
   PubMed Web of Science ®Google Scholar
• Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21(18):3440-6
   PubMed Web of Science ®Google Scholar
• Sprent J, Surh CD. Knowing one's self: central tolerance revisited. Nat Immunol 2003;4(4):303-4
   Google Scholar
• GERSHON RK. A disquisition on suppressor T cells. Transplant Rev 1975;26:170-85
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155(3):1151-64
   PubMed Web of Science ®Google Scholar
• Powrie F, Leach MW, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5(11):1461-71
   PubMed Web of Science ®Google Scholar
• Hall BM, Pearce NW, Gurley KE, et al. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med 1990;171(1):141-57
   PubMed Web of Science ®Google Scholar
• Franzke A, Hunger JK, Dittmar KE, et al. Regulatory T-cells in the control of immunological diseases. Ann Hematol 2006;85(11):747-58
   PubMed Web of Science ®Google Scholar
• BACH JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003;3(3):189-98
   PubMed Web of Science ®Google Scholar
• Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2(6):389-400
   PubMed Web of Science ®Google Scholar
• Rudensky AY, Gavin M, Zheng Y. FOXP3 and NFAT: partners in tolerance. Cell 2006;126(2):253-6
   PubMed Web of Science ®Google Scholar
• Marson A, Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007;445(7130):931-5
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10(12):1969-80
   PubMed Web of Science ®Google Scholar
• Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164(1):183-90
   PubMed Web of Science ®Google Scholar
• Tanchot C, Vasseur F, Pontoux C, et al. Immune regulation by self-reactive T cells is antigen specific. J Immunol 2004;172(7):4285-91
   Google Scholar
• Masteller EL, Warner MR, Tang Q, et al. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol 2005;175(5):3053-9
   PubMed Web of Science ®Google Scholar
• Jaeckel E, Von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 2005;54(2):306-310
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167(3):1245-53
   PubMed Web of Science ®Google Scholar
• McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16(2):311-23
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3(2):135-42
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Tangye SG, et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006;107(7):2830-8
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4(4):330-6
   PubMed Web of Science ®Google Scholar
• Kasprowicz DJ, Smallwood PS, Tyznik AJ, et al. Scurfin (FoxP3) controls T-dependent immune responses in vivo through regulation of CD4+ T cell effector function. J Immunol 2003;171(3):1216-23
   PubMed Web of Science ®Google Scholar
• Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002;39(8):537-45
   PubMed Web of Science ®Google Scholar
• Roncador G, Garcia JF, Garcia JF, et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 2005;19(12):2247-53
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3(3):253-7
   PubMed Web of Science ®Google Scholar
• Papiernik M, De Moraes ML, Pontoux C, et al. Regulatory CD4 T cells: expression of IL-2Rα chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998;10(4):371-8
   PubMed Web of Science ®Google Scholar
• Bopp T, Becker C, Klein M, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007;204(6):1303-10
   PubMed Web of Science ®Google Scholar
• Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007;7(11):875-88
   PubMed Web of Science ®Google Scholar
• Von Boehmer H. Peptide-based instruction of suppressor commitment in naive T cells and dynamics of immunosuppression in vivo. Scand J Immunol 2005;62(Suppl 1):49-54
   Google Scholar
• Hsieh CS, Liang Y, Tyznik AJ, et al. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity 2004;21(2):267-77
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Piccirillo CA, Mendez S, et al. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002;420(6915):502-7
   PubMed Web of Science ®Google Scholar
• Seddon B, Mason D. The third function of the thymus. Immunol Today 2000;21(2):95-9
   PubMedGoogle Scholar
• Yamagiwa S, Gray JD, Hashimoto S, et al. A role for TGF-β in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001;166(12):7282-9
   PubMed Web of Science ®Google Scholar
• Dieckmann D, Bruett CH, Ploettner H, et al. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 2002;196(2):247-53
   PubMed Web of Science ®Google Scholar
• Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389(6652):737-42
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Bacchetta R, Bordignon C, et al. Type 1 T regulatory cells. Immunol Rev 2001;182:68-79
   PubMed Web of Science ®Google Scholar
• Noble A, Giorgini A, Leggat JA. Cytokine-induced IL-10-secreting CD8 T cells represent a phenotypically distinct suppressor T-cell lineage. Blood 2006;107(11):4475-83
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198(4):569-80
   PubMed Web of Science ®Google Scholar
• Taylor PA, Friedman TM, Korngold R, et al. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002;99(12):4601-9
   PubMed Web of Science ®Google Scholar
• Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99(10):3493-9
   PubMed Web of Science ®Google Scholar
• Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001;193(11):1311-8
   PubMed Web of Science ®Google Scholar
• SAKAGUCHI S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol 2004;22:531-62
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163(10):5211-8
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tanaka J, Kjaergaard J, et al. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002;25(3):207-17
   PubMed Web of Science ®Google Scholar
• Sutmuller RP, Van Duivenvoorde LM, Van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194(6):823-32
   PubMed Web of Science ®Google Scholar
• Steitz J, Bruck J, Lenz J, et al. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon α-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001;61(24):8643-6
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168(9):4272-6
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61(12):4766-72
   PubMed Web of Science ®Google Scholar
• Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169(5):2756-61
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11(4):1467-73
   PubMed Web of Science ®Google Scholar
• Javia LR, Rosenberg SA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 2003;26(1):85-93
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13(3):902-11
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24(34):5373-80
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108(9):2957-64
   PubMed Web of Science ®Google Scholar
• Liu VC, Wong LY, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-β. J Immunol 2007;178(5):2883-92
   PubMed Web of Science ®Google Scholar
• Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007;178(4):2155-62
   PubMed Web of Science ®Google Scholar
• Larmonier N, Marron M, Zeng Y, et al. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10. Cancer Immunol Immunother 2007;56(1):48-59
   PubMed Web of Science ®Google Scholar
• Tanijiri T, Shimizu T, Uehira K, et al. Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol 2007;82(3):576-84
   Google Scholar
• Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3(3):199-210
   PubMed Web of Science ®Google Scholar
• Von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003;3(3):223-32
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167(3):1137-40
   PubMed Web of Science ®Google Scholar
• Van Maurik A, Herber M, Wood KJ, et al. Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: implications for anti-CD154 immunotherapy. J Immunol 2002;169(10):5401-4
   Google Scholar
• Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001;194(6):847-53
   PubMed Web of Science ®Google Scholar
• Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006;66(11):5716-22
   PubMed Web of Science ®Google Scholar
• Barnett B, Kryczek I, Cheng P, et al. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005;54(6):369-77
   PubMed Web of Science ®Google Scholar
• Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7(11):880-7
   PubMed Web of Science ®Google Scholar
• June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117(6):1466-76
   PubMed Web of Science ®Google Scholar
• Peng L, Kjaergaard J, Plautz GE, et al. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 2002;169(9):4811-21
   PubMedGoogle Scholar
• Diehl V, Von Kalle C, Fonatsch C, et al. The cell of origin in Hodgkin's disease. Semin Oncol 1990;17(6):660-72
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99(12):4283-97
   PubMed Web of Science ®Google Scholar
• Poppema S, Van Den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 2000;10(5):345-50
   PubMed Web of Science ®Google Scholar
• Dukers DF, Jaspars LH, Vos W, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and-negative cases of Hodgkin's disease. J Pathol 2000;190(2):143-9
   PubMed Web of Science ®Google Scholar
• Herbst H, Foss HD, Samol J, et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996;87(7):2918-29
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001;97(1):250-5
   PubMed Web of Science ®Google Scholar
• Ohshima K, Akaiwa M, Umeshita R, et al. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 2001;38(4):368-75
   PubMed Web of Science ®Google Scholar
• Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 2003;170(12):6183-9
   PubMed Web of Science ®Google Scholar
• Tesch H, Gunther A, Abts H, et al. Expression of interleukin-2R α and interleukin-2R β in Hodgkin's disease. Am J Pathol 1993;142(6):1714-20
   PubMed Web of Science ®Google Scholar
• Hsu SM, Lin J, Xie SS, et al. Abundant expression of transforming growth factor-β1 and -β2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum Pathol 1993;24(3):249-55
   PubMed Web of Science ®Google Scholar
• Marshall NA, Culligan DJ, Tighe J, et al. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol 2007;35(4):596-604
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Lambley E, Duraiswamy J, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 2006;108(7):2280-9
   PubMed Web of Science ®Google Scholar
• Blois SM, Ilarregui JM, Tometten M, et al. A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 2007;13(12):1450-7
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007;110(4):1326-9
   PubMed Web of Science ®Google Scholar
• Garin MI, Chu CC, Golshayan D, et al. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007;109(5):2058-65
   PubMed Web of Science ®Google Scholar
• Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007;104(32):13134-9
   PubMed Web of Science ®Google Scholar
• Van Den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999;154(6):1685-91
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005;65(13):5516-9
   PubMed Web of Science ®Google Scholar
• Maggio EM, Van Den Berg A, Visser L, et al. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer 2002;99(5):665-72
   Google Scholar
• Lee I, Wang L, Wells AD, et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005;201(7):1037-44
   PubMed Web of Science ®Google Scholar
• Klimm B, Schnell R, Diehl V, et al. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 2005;90(12):1680-92
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359(9323):2065-071
   PubMed Web of Science ®Google Scholar
• Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365(9475):1934-41
   PubMed Web of Science ®Google Scholar
• Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996;14(4):1291-6
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Peggs KS, Blundell E, et al. A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft. Leuk Lymphoma 2007;48(5):881-4
   PubMed Web of Science ®Google Scholar
• Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23(7):1522-9
   PubMed Web of Science ®Google Scholar
• Spencer A, Reed K, Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 2007;37(11):760-6
   PubMedGoogle Scholar
• Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98(2):310-4
   PubMed Web of Science ®Google Scholar
• Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62(13):3736-42
   PubMed Web of Science ®Google Scholar
• Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005;23(21):4669-78
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004;10(16):5327-34
   PubMed Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25(19):2764-9
   PubMed Web of Science ®Google Scholar
• Lucas KG, Salzman D, Garcia A, et al. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004;100(9):1892-901
   PubMed Web of Science ®Google Scholar
• Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004;200(12):1623-33
   PubMed Web of Science ®Google Scholar
• Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11(3):181-7
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120(12):2723-33
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007;26(25):3699-703
   PubMed Web of Science ®Google Scholar
• Kirkman RL, Barrett LV, Gaulton GN, et al. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985;162(1):358-62
   PubMed Web of Science ®Google Scholar
• Schnell R, Borchmann P, Staak JO, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003;14(5):729-36
   PubMed Web of Science ®Google Scholar
• Barth S, Schnell R, Diehl V, et al. Development of immunotoxins for potential clinical use in Hodgkin's disease. Ann Oncol 1996;7(Suppl 4):135-41
   Google Scholar
• Vlad G, Ho EK, Vasilescu ER, et al. Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol 2007;18(1):13-21
   PubMed Web of Science ®Google Scholar
• Attia P, Powell DJ Jr, Maker AV, et al. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother 2006;29(2):208-14
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 2006;7(10):1301-11
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007;179(7):4919-28
   PubMed Web of Science ®Google Scholar
• Foss FM. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000;1(2):110-6; discussion 7
   PubMedGoogle Scholar
• Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117(11):3383-92
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Curran MA, et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116(7):1935-45
   PubMed Web of Science ®Google Scholar
• Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006;176(11):6434-42
   PubMed Web of Science ®Google Scholar
• Sutmuller RP, Den Brok MH, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006;116(2):485-94
   PubMed Web of Science ®Google Scholar
• Peng G, Guo Z, Kiniwa Y, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005;309(5739):1380-4
   PubMed Web of Science ®Google Scholar
• Takeda I, Ine S, Killeen N, et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 2004;172(6):3580-9
   PubMed Web of Science ®Google Scholar
• Vu MD, Xiao X, Gao W, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007;110(7):2501-10
   PubMed Web of Science ®Google Scholar
• Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204(6):1257-65
   PubMed Web of Science ®Google Scholar
• Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 2004;10(22):7529-39
   PubMed Web of Science ®Google Scholar
• Press OW, Leblanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001;19(22):4238-44
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348(24):2386-95
   PubMed Web of Science ®Google Scholar
• Tesch H, Diehl V, Lathan B, et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998;92(12):4560-7
   PubMed Web of Science ®Google Scholar